Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB036C in Advanced Solid Tumors
NCT05642949Phase 2Not yet recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MHB036C in solid tumor, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), pancreatic ductal adenocarcinoma (PDAC), head and neck squamous cell carcinoma (HNSCC), sponsored by Minghui Pharmaceutical, Inc.. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
MHB036C
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)pancreatic ductal adenocarcinoma (PDAC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05642949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642949.